Glaukos Completes Enrollment in PRESERFLO MicroShunt Pivotal Study
Aliso Viejo, California, July 27, 2026 Glaukos Corporation announced the completion of patient enrollment in its U.S. 510(k) pivotal...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Aliso Viejo, California, July 27, 2026 Glaukos Corporation announced the completion of patient enrollment in its U.S. 510(k) pivotal...
TELFORD, Pennsylvania, June 22, 2026 Draeger, Inc., the U.S. headquarters of global medical technology leader Dräger, has announced that...
PHILADELPHIA, Nov. 12, 2025—Meduloc announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its...
